Company intelligence / Profile preview

Alvox Bio

Ownership: Private
Development stage: Preclinical

Overview

Alvox Bio is a leading Israeli CRO specializing in custom 3D bioprinting solutions for drug discovery, preclinical testing, and personalized medicine. The company offers advanced patient-derived tumor organoid models, safety/toxicity studies using healthy donor tissues, and in vivo validation of bioprinted tissues. Their technology bridges the gap between in vitro and in vivo research by providing highly realistic tissue environments for more predictive drug screening outcomes.

Therapeutic areas: OncologyOther
Modalities: 3D bioprinted tissue modelsOrganoid modelsBiomaterials
Industry: Drug Discovery Services

Beyond the preview

Go deeper on Alvox Bio.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Alvox Bio.

Explore the full profile